35309-53-6

Usage

Uses

Used in Pharmaceutical Industry:
CYCLO(-ASP-ASP) is used as a pharmaceutical agent for its potential antimicrobial, antitumor, and immunomodulatory effects. Its cyclic structure enhances its stability and resistance to enzymatic degradation, making it a promising candidate for the development of new drugs with improved efficacy and reduced side effects.
Used in Drug Delivery Systems:
CYCLO(-ASP-ASP) is used as a carrier in drug delivery systems due to its stability and ability to penetrate cell membranes. Its unique structure allows for the development of novel drug delivery systems that can improve the bioavailability and therapeutic outcomes of various drugs, particularly for challenging targets such as cancer cells.
Used in Antimicrobial Applications:
CYCLO(-ASP-ASP) is used as an antimicrobial agent for its potential to target and eliminate harmful microorganisms. Its cyclic structure and resistance to enzymatic degradation contribute to its effectiveness in combating infections and reducing the risk of antibiotic resistance.
Used in Antitumor Applications:
CYCLO(-ASP-ASP) is used as an antitumor agent for its potential to inhibit the growth and progression of tumors. Its unique structure and biological activities make it a promising candidate for the development of new cancer therapies, particularly for challenging cancer types.
Used in Immunomodulatory Applications:
CYCLO(-ASP-ASP) is used as an immunomodulatory agent for its potential to modulate the immune system and enhance the body's natural defense mechanisms against diseases. Its unique structure and biological activities make it a promising candidate for the development of new immunotherapies and vaccines.

Upstream product

• 160940-47-6 diketopiperazine of L-aspartic acid dibenzyl ester 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 71989-14-5 Fmoc-(tBu)Asp-OH 
• 187671-16-5 Fmoc-Asp-OFm 
• 56-84-8 L-Aspartic acid 
• 13798-75-9 N^α-t-butoxycarbonylaspartic acid α-N-hydroxysuccinimide ester β-benzyl ester 

Downstream Products

• 160940-54-5 Bn-L-Phe-L-Phe-(diketo-L-Asp)-L-Phe-L-Phe-Bn 
• 160940-48-7 Bn-Gly-(diketo-L-Asp)-Gly-Bn 
• 160940-50-1 Bn-L-Val-(diketo-L-Asp)-L-Val-Bn 
• 160940-51-2 Bn-L-Tyr-(diketo-L-Asp)-L-Tyr-Bn 
• 160940-49-8 Bn-L-Ala-(diketo-L-Asp)-L-Ala-Bn 
• 178456-32-1 Bn-L,D-Phe-(diketo-L-Asp)-L,D-Phe-Bn 

Relevant academic research and scientific papers

Synthetic method of cyclic dipeptide containing aspartic acid and glutamic acid

The invention discloses a synthetic method of cyclic dipeptide containing aspartic acid and glutamic acid, which comprises the following steps: by taking Fmoc-Asp (OtBu)-OH or Fmoc-Glu (OtBu)-OH as a raw material, reacting with 9-fluorene methanol to obtain fluorene methyl ester of fully protected amino acid, and then removing side chain tert-butoxy to obtain protected amino acid Fmoc-Asp-OFm or Fmoc-Glu-OFm; 2-CTC Resin resin is used as a carrier to be bonded with Fmoc-Asp-OFm or Fmoc-Glu-OFm side chain gamma-carboxyl, solid-phase cyclization is carried out to synthesize full-protection cyclic dipeptide, and the cyclic dipeptide with aspartic acid or glutamic acid at the carbon end is obtained through cutting and cracking. According to the method, 9-fluorene methanol is introduced to protect carboxyl, the carboxyl can be smoothly removed in the solid-phase synthesis process of the dipeptide, the whole process is easy to operate, the solid-phase cyclization efficiency is high, the purity is high, and the method can be suitable for batch synthesis of cyclic dipeptide with aspartic acid or glutamic acid at the carbon end.

Bio-based epoxy resin precursor containing cyclic amide structure, and preparation method and application thereof

The invention discloses a bio-based epoxy resin precursor containing a cyclic amide structure, and also discloses a preparation method and application of the bio-based epoxy resin precursor containingthe cyclic amide structure. The preparation method comp

Template-assisted photodimerization of: N -unprotected uracil derivatives: Selective formation of the cis - Syn photodimer

A UV light-induced photodimerization of 5-[(imidazol-1-yl)methyl]uracil using glutamate- and aspartate-derived cyclic dipeptides (2,5-diketopiperazines-DKPs) as templates was investigated. Dual salt bridge formation between imidazole side chains and carboxylic acids resulted in the preorganization of the uracil monomers and the preferential formation of the cis-syn photodimer.

β-Lactam derivatives as enzyme inhibitors: N-substituted derivatives of (S)-4-oxoazetidine-2-carboxylate as inhibitors of elastase and papain

N-Alkyl and N-acyl substituted 4-oxoazetidine-2-carboxylates are synthesized and evaluated as inhibitors of the proteases porcine pancreatic elastase (PPE) and papain. The compounds are obtained by alkylation or acylation at the nitrogen of benzyl (S)-4-oxoazetidine-2-carboxylate, which is synthesized by a modified literature procedure. The enzymatic assays prove some derivatives to be effective inhibitors of PPE and/or papain. The N-BOC protected amino acid derivatives 10 and 13 inhibit PPE reversibly with K(I)-values in the micromolar range. On the other hand, papain is inactivated irreversibly by benzyl (S)-2-(benzyloxycarbonyl)azetidin-1-acetate (6).

Macromolecular self-assembly of diketopiperazine tetrapeptides

Basic solutions of tetrapeptides derived from L-aspartic acid diketopiperazines are shown to form microcapsules when acidified to pH 2.4. An initial structure-activity study clearly demonstrates that a very delicate balance exists between the tetrapeptide